Loading…
Ken GriffinHeld
Citadel Advisors · Q2 2026
$4.64M
758.3K shares · 0.0% of portfolio
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. (VNDA) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Washington, United States and has 533 employees. The company is worth $244.87M. Revenue was $216.11M in fiscal 2025, up 8.7% from the year before. It reported a net loss of $220.47M. The share price is 59.3% below its 52-week high of $9.94. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Cliff Asness (AQR Capital Management), at $21.41M. In that quarter, 1 of them opened or added to the position and 2 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -75.1% over 5Y.
today you would have $235.40▼ -76.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 17 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $8.82 | $4.79 | $4.22 | $7.39 | $15.69 | $13.14 | $16.41 | $26.13 | $15.20 | $15.95 | $9.31 | $14.32 | $12.41 | $3.70 | $4.76 | $9.46 | $11.25 | |
| P/E |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| AMRNAmarin Corp Plc\uk | $11.60 | — | 0.5x | 0.00% | -5.97% | $245.02M |
| QSIQuantum-Si Inc | $1.12 | — | 1.4x | 0.00% | -49.11% | $245.15M |
| PALIPalisade Bio Inc | $1.41 | 2.4x | 2.0x | 0.00% | -51.37% | $245.72M |
| IMRXImmuneering Corp | $3.81 |
| 34.6x |
| — |
| — |
| 105.5x |
| 67.2x |
| 27.1x |
| 31.3x |
| 7.8x |
| 54.4x |
| — |
| — |
| — |
| 26.0x |
| — |
| — |
| — |
| 37.8x |
| — |
| P/S | 3.9x | 2.4x | 1.4x | 1.3x | 1.6x | 3.3x | 2.9x | 3.9x | 7.1x | 4.2x | 4.8x | 3.7x | 11.9x | 12.3x | 3.2x | 4.3x | 7.4x | 66.8x |
| P/B | 3.7x | 1.6x | 0.5x | 0.4x | 0.8x | 1.7x | 1.6x | 2.1x | 5.0x | 5.3x | 5.4x | 3.0x | 3.7x | 9.4x | 10.6x | 4.0x | 7.0x | 13.2x |
| EPS | -$3.74 | -$0.33 | $0.04 | $0.11 | $0.58 | $0.42 | $2.11 | $0.48 | -$0.35 | -$0.41 | -$0.94 | $0.55 | -$0.69 | -$1.01 | -$0.35 | $0.25 | -$1.33 |
| Profit margin | -9.43% | -102.02% | -9.51% | 1.30% | 2.47% | 12.34% | 9.40% | 50.86% | 13.05% | -9.43% | -12.33% | -36.27% | 40.25% | -62.15% | -87.44% | -31.35% | 20.14% | -788.46% |
| ROE | -3.51% | -67.38% | -3.51% | 0.46% | 1.19% | 6.57% | 5.15% | 28.12% | 9.15% | -11.85% | -13.71% | -29.97% | 12.55% | -47.72% | -288.91% | -29.28% | 19.06% | -155.70% |
Median of the years shown; P/E years above 200x are left out.
| — |
| 1.3x |
| 0.00% |
| -52.15% |
| $246.5M |
| LCTXLineage Cell Therapeutics, Inc. | $0.98 | — | 4.1x | 0.00% | -60.06% | $247.42M |
| CATXPerspective Therapeutics, Inc. | $2.17 | — | 0.8x | 0.00% | -39.57% | $247.71M |